Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (47) 47
life sciences & biomedicine (46) 46
oncology (38) 38
humans (36) 36
melanoma (30) 30
female (27) 27
male (26) 26
middle aged (26) 26
melanoma - drug therapy (23) 23
aged (22) 22
adult (18) 18
tumors (17) 17
melanoma - pathology (15) 15
aged, 80 and over (14) 14
metastasis (14) 14
patients (14) 14
immunotherapy (13) 13
ipilimumab (13) 13
pembrolizumab (12) 12
melanoma - mortality (11) 11
skin neoplasms - drug therapy (11) 11
antibodies, monoclonal, humanized - therapeutic use (9) 9
cancer (9) 9
clinical trials (9) 9
mutation (9) 9
skin neoplasms - pathology (9) 9
care and treatment (8) 8
research (8) 8
treatment outcome (8) 8
abridged index medicus (7) 7
analysis (7) 7
antibodies, monoclonal, humanized - adverse effects (7) 7
antineoplastic agents, immunological - therapeutic use (7) 7
biological and medical sciences (7) 7
disease-free survival (7) 7
medical sciences (7) 7
neoplasm staging (7) 7
pd-1 protein (7) 7
skin neoplasms - mortality (7) 7
survival (7) 7
antineoplastic agents (6) 6
antineoplastic agents - therapeutic use (6) 6
cancer therapies (6) 6
drug therapy (6) 6
medical research (6) 6
melanoma - genetics (6) 6
melanoma - secondary (6) 6
protein kinase inhibitors - therapeutic use (6) 6
proto-oncogene proteins b-raf - antagonists & inhibitors (6) 6
proto-oncogene proteins b-raf - genetics (6) 6
antibodies, monoclonal - adverse effects (5) 5
antibodies, monoclonal - therapeutic use (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
cell biology (5) 5
chemistry (5) 5
chemotherapy (5) 5
confidence intervals (5) 5
dermatology (5) 5
dosage and administration (5) 5
dose-response relationship, drug (5) 5
drug therapy, combination (5) 5
ipilimumab - therapeutic use (5) 5
melanoma - metabolism (5) 5
metastases (5) 5
patient outcomes (5) 5
retrospective studies (5) 5
toxicity (5) 5
adolescent (4) 4
antineoplastic agents - adverse effects (4) 4
antineoplastic agents, immunological - adverse effects (4) 4
biochemistry & molecular biology (4) 4
complications and side effects (4) 4
general & internal medicine (4) 4
health aspects (4) 4
human necessities (4) 4
hygiene (4) 4
immune checkpoint (4) 4
medical or veterinary science (4) 4
medicine, experimental (4) 4
medicine, general & internal (4) 4
medicine, research & experimental (4) 4
metallurgy (4) 4
mitogen-activated protein kinase kinases - antagonists & inhibitors (4) 4
neoplasm metastasis (4) 4
organic chemistry (4) 4
peptides (4) 4
pharmacology. drug treatments (4) 4
prognosis (4) 4
research & experimental medicine (4) 4
skin cancer (4) 4
skin neoplasms - genetics (4) 4
specific therapeutic activity of chemical compounds ormedicinal preparations (4) 4
survival analysis (4) 4
survival rate (4) 4
antibodies (3) 3
antibodies, monoclonal - administration & dosage (3) 3
antibodies, monoclonal, humanized - administration & dosage (3) 3
antimitotic agents (3) 3
antineoplastic agents - pharmacology (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
by Robert, Caroline, Prof and Ribas, Antoni, Prof and Schachter, Jacob, Prof and Arance, Ana, MD and Grob, Jean-Jacques, Prof and Mortier, Laurent, Prof and Daud, Adil, Prof and Carlino, Matteo S, MB and McNeil, Catriona M, MD and Lotem, Michal, Prof and Larkin, James M G, Prof and Lorigan, Paul, Prof and Neyns, Bart, Prof and Blank, Christian U, Prof and Petrella, Teresa M, MD and Hamid, Omid, MD and Su, Shu-Chih, PhD and Krepler, Clemens, MD and Ibrahim, Nageatte, MD and Long, Georgina V, Prof
The lancet oncology, ISSN 1470-2045, 2019, Volume 20, Issue 9, pp. 1239 - 1251
Hematology, Oncology, and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Ipilimumab | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Pembrolizumab versus Ipilimumab in Advanced Melanoma
by Robert, Caroline and Schachter, Jacob and Long, Georgina V and Arance, Ana and Grob, Jean Jacques and Mortier, Laurent and Daud, Adil and Carlino, Matteo S and McNeil, Catriona and Lotem, Michal and Larkin, James and Lorigan, Paul and Neyns, Bart and Blank, Christian U and Hamid, Omid and Mateus, Christine and Shapira-Frommer, Ronnie and Kosh, Michele and Zhou, Honghong and Ibrahim, Nageatte and Ebbinghaus, Scot and Ribas, Antoni and KEYNOTE-006 Investigators and KEYNOTE-006 investigators
The New England journal of medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 26, pp. 2521 - 2532
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Young Adult | Antineoplastic Agents - adverse effects | Skin Neoplasms - mortality | Melanoma - drug therapy | Adolescent | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Programmed Cell Death 1 Receptor - immunology | Melanoma - mortality | Prognosis | Melanoma | Dosage and administration | Research | Comparative analysis | Drug therapy | PD-1 protein | Toxicity | Body weight | Patients | Pembrolizumab | Chemotherapy | Immune checkpoint | Cell death | Immunotherapy | Antitumor activity | Mutation | Apoptosis | Immune system | Fees & charges | Laboratories | Equity | Equity stake | Response rates | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
by Schachter, Jacob and Ribas, Antoni and Long, Georgina V and Arance, Ana and Grob, Jean-Jacques and Mortier, Laurent and Daud, Adil and Carlino, Matteo S and McNeil, Catriona and Lotem, Michal and Larkin, James and Lorigan, Paul and Neyns, Bart and Blank, Christian and Petrella, Teresa M and Hamid, Omid and Zhou, Honghong and Ebbinghaus, Scot and Ibrahim, Nageatte and Robert, Caroline
The Lancet (British edition), ISSN 0140-6736, 10/2017, Volume 390, Issue 10105, pp. 1853 - 1862
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Pharmaceutical industry | Analysis | Immunoglobulins | Immune response | Melanoma | Clinical trials | Oncology | Lymphocytes T | Metastasis | FDA approval | Patients | Survival | Studies | Immune checkpoint | Immunotherapy | Cancer | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
by Cristescu, Razvan and Mogg, Robin and Ayers, Mark and Albright, Andrew and Murphy, Erin and Yearley, Jennifer and Sher, Xinwei and Liu, Xiao Qiao and Lu, Hongchao and Nebozhyn, Michael and Zhang, Chunsheng and Lunceford, Jared K and Joe, Andrew and Cheng, Jonathan and Webber, Andrea L and Ibrahim, Nageatte and Plimack, Elizabeth R and Ott, Patrick A and Seiwert, Tanguy Y and Ribas, Antoni and McClanahan, Terrill K and Tomassini, Joanne E and Loboda, Andrey and Kaufman, David
Science (American Association for the Advancement of Science), ISSN 0036-8075, 10/2018, Volume 362, Issue 6411, p. 197
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Transcriptome | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Genetic Markers | Cell Cycle Checkpoints | Neoplasms - therapy | Neoplasms - genetics | Antineoplastic Agents, Immunological - therapeutic use | Immunotherapy | Inflammation - genetics | T-Lymphocytes - immunology | Tumor Burden - genetics | Biomarkers, Tumor - genetics | Mutation | Molecular Targeted Therapy - methods | Cell receptors | Physiological aspects | Diagnosis | Biological markers | Identification and classification | Methods | Cancer | PD-1 protein | Genomics | Clinical trials | Genomes | Biology | Lymphocytes T | Microsatellite instability | Subgroups | Anticancer properties | Proteins | Cell activation | Pembrolizumab | Databases | Antigenicity | Precision medicine | Lymphocytes | Deoxyribonucleic acid--DNA | Medical research | Stability | Mortality | Melanoma | Data processing | Inflammation | Gene expression | Patients | Immune checkpoint | Cell death | Correlation analysis | PD-L1 protein | Monoclonal antibodies | Biomarkers | Ligands | Antitumor activity | Cutoffs | Solid tumors | Apoptosis | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
by Eggermont, Alexander M.M and Blank, Christian U and Mandala, Mario and Long, Georgina V and Atkinson, Victoria and Dalle, Stéphane and Haydon, Andrew and Lichinitser, Mikhail and Khattak, Adnan and Carlino, Matteo S and Sandhu, Shahneen and Larkin, James and Puig, Susana and Ascierto, Paolo A and Rutkowski, Piotr and Schadendorf, Dirk and Koornstra, Rutger and Hernandez-Aya, Leonel and Maio, Michele and van den Eertwegh, Alfonsus J.M and Grob, Jean-Jacques and Gutzmer, Ralf and Jamal, Rahima and Lorigan, Paul and Ibrahim, Nageatte and Marreaud, Sandrine and van Akkooi, Alexander C.J and Suciu, Stefan and Robert, Caroline
The New England journal of medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 19, pp. 1789 - 1801
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Adjuvants, Immunologic - adverse effects | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Survival Rate | Disease-Free Survival | B7-H1 Antigen - antagonists & inhibitors | Melanoma - drug therapy | Intention to Treat Analysis | Quality of Life | Aged | B7-H1 Antigen - analysis | Infusions, Intravenous | Melanoma - surgery | Neoplasm Staging | Melanoma - mortality | Diagnosis | Drug therapy | Patients | Health aspects | Melanoma | Medical research | Lymphatic system | PD-1 protein | Committees | Metastasis | Survival | Skin cancer | Pembrolizumab | Hospitals | Motivation | PD-L1 protein | Myositis | Death | Mutation | Tumors | Cancer | Index Medicus | Abridged Index Medicus | Placebos | Placebos (Medicine) | Adjuvant treatment of cancer | Tractament adjuvant del càncer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
by Flaherty, Keith T and Infante, Jeffery R and Daud, Adil and Gonzalez, Rene and Kefford, Richard F and Sosman, Jeffrey and Hamid, Omid and Schuchter, Lynn and Cebon, Jonathan and Ibrahim, Nageatte and Kudchadkar, Ragini and Burris, Howard A and Falchook, Gerald and Algazi, Alain and Lewis, Karl and Long, Georgina V and Puzanov, Igor and Lebowitz, Peter and Singh, Ajay and Little, Shonda and Sun, Peng and Allred, Alicia and Ouellet, Daniele and Kim, Kevin B and Patel, Kiran and Weber, Jeffrey
The New England journal of medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 18, pp. 1694 - 1703
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Tumors of the skin and soft tissue. Premalignant lesions | Biological and medical sciences | General aspects | Medical sciences | Dermatology | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Imidazoles - pharmacokinetics | Fever - chemically induced | Drug Therapy, Combination - adverse effects | Melanoma - genetics | Adult | Female | Imidazoles - therapeutic use | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | MAP Kinase Signaling System - drug effects | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged | Pyridones - therapeutic use | Mutation | Pyridones - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Patient outcomes | Melanoma | Product/Service Evaluations | Research | Antineoplastic agents | Antimitotic agents | Gene mutations | Causes of | Genetic aspects | Dosage and administration | Drug therapy, Combination | Drug therapy | Cell survival | Protein kinase | Skin diseases | MAP kinase | Kinases | Patients | Drug dosages | Fever | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
by Ascierto, Paolo Antonio and Ferrucci, Pier Francesco and Fisher, Rosalie and Del Vecchio, Michele and Atkinson, Victoria and Schmidt, Henrik and Schachter, Jacob and Queirolo, Paola and Long, Georgina V and Di Giacomo, Anna Maria and Svane, Inge Marie and Lotem, Michal and Bar-Sela, Gil and Couture, Felix and Mookerjee, Bijoyesh and Ghori, Razi and Ibrahim, Nageatte and Moreno, Blanca Homet and Ribas, Antoni
Nature medicine, ISSN 1078-8956, 2019, Volume 25, Issue 6, pp. 941 - 946
Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Cell Biology | Research & Experimental Medicine | Drug therapy, Combination | Drug therapy | Melanoma | Testing | Antimitotic agents | Development and progression | Care and treatment | Comparative analysis | Antineoplastic agents | Therapy | Statistical analysis | PD-1 protein | Transaminase | MEK inhibitors | Blocking antibodies | Antibodies | Durability | Survival | Fever | Confidence intervals | Pembrolizumab | Pneumonitis | Inhibitors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
by Ribas, Antoni and Lawrence, Donald and Atkinson, Victoria and Agarwal, Sachin and Miller, Wilson H and Carlino, Matteo S and Fisher, Rosalie and Long, Georgina V and Hodi, F. Stephen and Tsoi, Jennifer and Grasso, Catherine S and Mookerjee, Bijoyesh and Zhao, Qing and Ghori, Razi and Moreno, Blanca Homet and Ibrahim, Nageatte and Hamid, Omid
Nature medicine, ISSN 1078-8956, 06/2019, Volume 25, Issue 6, pp. 936 - 940
Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Cell Biology | Research & Experimental Medicine | Antimitotic agents | Immunotherapy | Melanoma | Drug therapy, Combination | Metastasis | Antineoplastic agents | Drug therapy | Health aspects | Methods | Mitogen-activated protein kinases | Proto-oncogenes | Testing | Viral antibodies | Medical research | Biological products | Medicine, Experimental | Antibodies | Mitogens | Therapy | PD-1 protein | MEK inhibitors | MAP kinase | Kinases | Patients | Fever | Metastases | Confidence intervals | Pembrolizumab | Inhibitors | Protein kinase | Antitumor activity | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Ipilimumab associated hepatitis: imaging and clinicopathologic findings
by Kim, Kyung Won and Ramaiya, Nikhil H and Krajewski, Katherine M and Jagannathan, Jyothi P and Tirumani, Sree Harsha and Srivastava, Amitabh and Ibrahim, Nageatte
Investigational new drugs, ISSN 0167-6997, 8/2013, Volume 31, Issue 4, pp. 1071 - 1077
Hepatitis | Pathology | Immune-related adverse events | Medicine & Public Health | Ipilimumab | Imaging | Oncology | Pharmacology/Toxicology | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Toxicity: digestive system | Gastroenterology. Liver. Pancreas. Abdomen | Liver. Biliary tract. Portal circulation. Exocrine pancreas | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Drug toxicity and drugs side effects treatment | Other diseases. Semiology | Hepatitis - diagnostic imaging | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Hepatitis - pathology | Male | Tomography, X-Ray Computed | Ultrasonography | Aged, 80 and over | Adult | Female | Aged | Complications and side effects | Dosage and administration | Diagnosis | Risk factors | Studies | Medical imaging | Research | FDA approval | Cancer therapies | Patients | Immune system | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights